Form 4: Arrowhead Director Sells Shares Under 10b5-1 Plan

Arrowhead Pharmaceuticals Director William D. Waddill sold 8,367 shares of common stock in planned transactions.

Summary

• William D. Waddill, a Director at Arrowhead Pharmaceuticals, Inc. (ARWR), reported the sale of 8,367 shares of common stock.
• The sales occurred on December 19, 2025, and were executed pursuant to a Rule 10b5-1 trading plan.
• The transactions involved three separate sales: 2,416 shares at a weighted average price of $66.66, 5,451 shares at a weighted average price of $68.01, and 500 shares at a weighted average price of $68.53.
• Following these transactions, Mr. Waddill beneficially owns 56,563 shares of common stock.
• The reported beneficial ownership includes shares underlying Restricted Stock Units (RSUs) that are still subject to certain vesting conditions.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can sometimes be viewed negatively, the execution under a pre-arranged 10b5-1 plan mitigates concerns that the sale is based on new, adverse information. It's a routine personal financial management event for a director.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and automated transaction rather than a discretionary sale based on new, non-public information.

Negatives

• An insider sale, even under a 10b5-1 plan, reduces the director's direct equity stake in the company, which some investors might interpret as a lack of conviction, though this is mitigated by the pre-planned nature.

Risks

• No specific risks were mentioned in the filing beyond the inherent risk associated with any insider selling activity, which can sometimes be perceived negatively by the market.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• "/s/William Waddill" (Signature of Reporting Person)

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction. It does not provide information directly related to broader industry trends or competitive landscape within the pharmaceutical sector. The transaction itself is a common occurrence for executives and directors managing their personal portfolios, especially when executed under a 10b5-1 plan.

Comparison to Industry Standards

• NA

Related Party Transactions

• The sale of common stock by Director William D. Waddill constitutes a related party transaction, as it involves an insider of Arrowhead Pharmaceuticals, Inc.

Stakeholder Impact

• Shareholders: The sale slightly reduces the director's direct ownership stake, which could be viewed neutrally given the 10b5-1 plan, or slightly negatively by those who prefer insiders to increase their holdings.
• Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• No specific future actions or milestones for the company are mentioned in this filing.

Key Dates

Recommendation

The filing reports a routine insider stock sale executed under a pre-arranged 10b5-1 plan. This type of transaction is generally not considered a strong indicator of future stock performance, as it reflects personal financial planning rather than a reaction to new material information. Therefore, it does not provide a basis for changing an existing investment thesis, leading to a 'hold' recommendation based solely on this filing.

Keywords

Arrowhead Pharmaceuticals, ARWR, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Director, Equity Transaction, Pharmaceuticals